J Ruan1, M Ouyang1,2, W Zhang3, Y Luo4, D Zhou1. 1. Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China. 2. Department of Cardiovascule, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. 3. Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China. zhangwei3840@sina.com. 4. Department of Immunology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Abstract
PURPOSE: Our study aimed to explore the programmed death 1 (PD-1) expression on tumor-associated macrophage (TAM) in T cell non-Hodgkin lymphoma (T-NHL) and its relationship with lymphoma prognosis. The effect of PD-1 expression on the function of macrophages was also studied. METHODS: Multispectral image quantitative analysis was applied for detecting PD-1 expression on macrophages in T cell lymphoma tissues. The Kaplan-Meier analysis was performed to evaluate the value of PD-1 expression of TAM in predicting the overall survival of T-NHL. PD-1 overexpression THP-1-derived macrophage was constructed and was cocultured with Jurkat cells to explore the effect of PD-1 on macrophage function. RESULTS: In 17 T cell lymphoma cases, the 1-year overall survival rate was significantly lower in patients with higher PD-1 expression on TAMs (0.25 vs 0.86, p < 0.05). After co-cultured with Jurkat cells, classically activated (M1)-related markers on PD-1 overexpressed macrophages were significantly lower than those on controls, while the expressions of alternatively activated (M2) related markers were similar. The PD-1 overexpressed macrophages showed inhibited phagocytosis (4.42% vs 40.7%, p < 0.001) and increased IL-10 secretion (144.48 pg/ml vs 32.32 pg/ml, p < 0.001). CONCLUSION: High PD-1 expression on TAMs in T-NHL may predict poor prognosis. The PD-1 overexpression of macrophages significantly inhibited polarization of M1 macrophages and phagocytosis, and more IL-10 was excreted. These changes may enhance the pro-tumor effects of tumor microenvironment.
PURPOSE: Our study aimed to explore the programmed death 1 (PD-1) expression on tumor-associated macrophage (TAM) in T cell non-Hodgkin lymphoma (T-NHL) and its relationship with lymphoma prognosis. The effect of PD-1 expression on the function of macrophages was also studied. METHODS: Multispectral image quantitative analysis was applied for detecting PD-1 expression on macrophages in T cell lymphoma tissues. The Kaplan-Meier analysis was performed to evaluate the value of PD-1 expression of TAM in predicting the overall survival of T-NHL. PD-1 overexpression THP-1-derived macrophage was constructed and was cocultured with Jurkat cells to explore the effect of PD-1 on macrophage function. RESULTS: In 17 T cell lymphoma cases, the 1-year overall survival rate was significantly lower in patients with higher PD-1 expression on TAMs (0.25 vs 0.86, p < 0.05). After co-cultured with Jurkat cells, classically activated (M1)-related markers on PD-1 overexpressed macrophages were significantly lower than those on controls, while the expressions of alternatively activated (M2) related markers were similar. The PD-1 overexpressed macrophages showed inhibited phagocytosis (4.42% vs 40.7%, p < 0.001) and increased IL-10 secretion (144.48 pg/ml vs 32.32 pg/ml, p < 0.001). CONCLUSION: High PD-1 expression on TAMs in T-NHL may predict poor prognosis. The PD-1 overexpression of macrophages significantly inhibited polarization of M1 macrophages and phagocytosis, and more IL-10 was excreted. These changes may enhance the pro-tumor effects of tumor microenvironment.
Entities:
Keywords:
Programmed death 1; T cell lymphoma; Tumor microenvironment; Tumor-associated macrophage
Authors: Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Jacob P Smeltzer; Jason M Jones; Steven C Ziesmer; Deanna M Grote; Bing Xiu; Kay M Ristow; Zhi Zhang Yang; Grzegorz S Nowakowski; Andrew L Feldman; James R Cerhan; Anne J Novak; Stephen M Ansell Journal: Clin Cancer Res Date: 2014-04-11 Impact factor: 12.531
Authors: Alexander M Lesokhin; Stephen M Ansell; Philippe Armand; Emma C Scott; Ahmad Halwani; Martin Gutierrez; Michael M Millenson; Adam D Cohen; Stephen J Schuster; Daniel Lebovic; Madhav Dhodapkar; David Avigan; Bjoern Chapuy; Azra H Ligon; Gordon J Freeman; Scott J Rodig; Deepika Cattry; Lili Zhu; Joseph F Grosso; M Brigid Bradley Garelik; Margaret A Shipp; Ivan Borrello; John Timmerman Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Björn Engelbrekt Wahlin; Mohit Aggarwal; Santiago Montes-Moreno; Luis Francisco Gonzalez; Giovanna Roncador; Lidia Sanchez-Verde; Birger Christensson; Birgitta Sander; Eva Kimby Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531